1. Home
  2. News
  3. Alterity Therapeutics Ltd.
  4. Alterity Granted New Composition of Matter Patent in Europe
More Alterity Therapeutics Ltd. news
Alterity Therapeutics Ltd.ASX: ATH

Alterity Granted New Composition of Matter Patent in Europe

Aug 23, 2023 at 4:36 AM EDT · Issued by Alterity Therapeutics Ltd.

Filed with ASX · Aug 23, 2023 at 4:36 AM EDT · 3 pages · English

On 6ix: 6ix.com/news/alterity-granted-new-composition-of-matter-patent-in-europe

Alterity Therapeutics Ltd. on 6ix

Story so far

  • First Patient Enrolled in Europe in Phase II Clinical trialMar 8, 2023
  • ATH434 Phase 2 clinical launched in EuropeAug 25, 2022

Earlier from Alterity Therapeutics

  • Alterity receives a $4.74 million R&D Tax RefundAug 15, 2023
  • Ph 2 Data Monitoring Committee Recommends Continuing TrialJul 26, 2023
  • Investor PresentationJun 22, 2023
  • ATH starts 2nd Phase 2 Study in Rare Parkinsonian DisorderMay 30, 2023
  • Appendix 4C and Quarterly Cash Flow ReportApr 27, 2023

Later from Alterity Therapeutics

  • Alterity Presents New Data on Multiple System AtrophyAug 31, 2023
  • Appendix 4E and Annual Report 2023Aug 31, 2023
  • ATH completes enrolment in ATH434-201 Phase 2 clinical trialNov 7, 2023
  • Alterity Therapeutics Raises $4.8M AUD in PlacementNov 21, 2023
  • Positive Efficacy Data for ATH434 in a Primate Model of PDDec 3, 2023
All Alterity Therapeutics news releases↗

Follow Alterity Therapeutics into a list and get an email when it puts out news.

Follow Alterity Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer